Actualités

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Merck (NYSE:MRK) plans to present more than 100 oncology abstracts at the 2026 ASCO Annual Meeting. The company will share five year outcomes from pivotal trials of KEYTRUDA combinations in melanoma and triple negative breast cancer. Merck will also highlight data on next generation antibody drug conjugates and individualized neoantigen therapies. For investors following NYSE:MRK, this ASCO 2026 update is at the center of Merck's core oncology focus. KEYTRUDA is a key part of its cancer...

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

The new solar farms boost Matrix’s Spanish portfolio, supporting grid reliability and long-term clean power supply.

Insightful Moves in the First Quarter of 2026

By Twesha Dikshit, Avinash P and Johann M Cherian May 13 (Reuters) - European shares ended higher on Wednesday, led by gains in mining stocks, though caution lingered as investors weighed the economic

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.

Merck overview and recent performance snapshot Merck (MRK) stock is drawing attention after a stretch of mixed returns, with a gain of 0.98% over the past day but declines of 0.69% over the past week and 7.45% over the past month. See our latest analysis for Merck. At a share price of $112.37, Merck’s short term share price momentum has cooled after a weaker 30 day share price return, even though its 1 year total shareholder return of 51.97% remains strong. If you are comparing Merck’s...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

The outlook lift comes on expectations of stronger momentum in the group’s life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

With an annual dividend yield of 3.06%, Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. On May 7, Citi analyst […]

Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer, with plans to move into Phase 3. These updates signal further external partnerships around KEYTRUDA combinations, adding to Merck's oncology pipeline as key patents approach expiry. For investors watching large pharma, Merck's focus on...

UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 30, Reuters reported that Merck & Co., Inc. (NYSE:MRK) surpassed first-quarter forecasts, with revenue of $16.3 billion, up 5% and beyond analysts’ $15.8 billion projection as per LSEG data. Keytruda sales went […]

UnitedHealth, Merck and QUALCOMM lead Zacks' top research picks as analysts highlight growth drivers, earnings trends and key risks.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular […]

The average American household spends about $519 a month on groceries, based on the latest BLS Consumer Expenditure Survey figure of $6,224 a year, and grocery prices are still rising: food-at-home prices were up 1.9% year over year as of March 2026. Add about $280 for utilities and roughly $100 for phone and internet, plus ... A $185,000 Portfolio That Covers Your Groceries, Utilities, and Phone Bill Every Month